Recent data from an individual patient data (IPD) meta-analysis of 17 randomized control trials including >100,000 women living in low-and middle-income countries found that multiple micronutrient supplementation (MMS) in pregnancy reduced the risk of low birth weight, preterm birth, and being born small for gestational age. Further, MMS reduced the risk of neonatal and infant mortality for females, and there was no evidence of increased risk among the 26 subgroups examined. The 2016 WHO antenatal care guidelines, which were released before the IPD meta-analysis, did not universally recommend MMS, noting: "There is some evidence of additional benefit … but there is also some evidence of risk." The guidelines suggest that MMS may increase the risk of neonatal mortality based on an exploratory subgroup analysis of 6 randomized trials. However, we identified several issues with this subgroup analysis. In this report we correct and update the subgroup analysis and show that there is no evidence that MMS increases the risk of neonatal mortality. There is growing scientific consensus that MMS containing iron and folic acid (IFA) is superior to Keywords: micronutrient supplementation, pregnancy, low birth weight, infant mortality, World Health Organization Micronutrient deficiencies in pregnancy are common and are associated with adverse birth outcomes (1). Prenatal multiple micronutrient supplementation (MMS) can improve outcomes, and our recently published individual patient data (IPD) metaanalysis showed that MMS decreased mortality for female neonates and provided greater reductions in the risk of low birth weight and preterm birth for infants born to undernourished and anemic women (2).
Micronutrient deficiencies in pregnancy are common and are associated with adverse birth outcomes (1) . Prenatal multiple micronutrient supplementation (MMS) can improve outcomes, and our recently published individual patient data (IPD) metaanalysis showed that MMS decreased mortality for female neonates and provided greater reductions in the risk of low birth weight and preterm birth for infants born to undernourished and anemic women (2) .
The 2016 WHO antenatal care guidelines do not universally recommend MMS, noting: "There is some evidence of additional benefit of MMN [multiple micronutrient] supplements containing 13-15 different micronutrients (including iron and folic acid) over iron and folic acid supplements alone, but there is also some evidence of risk" (2, 3) . The guidelines suggest that MMS may increase the risk of neonatal mortality based on an exploratory subgroup analysis of 6 randomized trials that used an iron-folic acid (IFA) control consisting of 60 mg Fe/d and 400 μg folic acid/d. There was a nonsignificant elevated risk of neonatal mortality in this subgroup (RR: 1.22; 95% CI: 0.95, 1.57) (3). The rationale for this exploratory analysis, and the reason for excluding trials based on the folic acid dose, were not stated.
Given the seemingly disparate findings between the recent IPD meta-analysis and the WHO subgroup analysis, we compared the methods and estimates in the published metaanalyses. We identified 4 issues in the neonatal mortality subgroup meta-analysis in the WHO guidelines, and we made the following changes: 1) corrected the Bhutta et al. estimate, which is consistent with the updated 2017 Cochrane Review (4); 2) included the omitted MINIMat study (5); 3) added 2 recently published trials (lipid-based supplements arms excluded) (6, 7); and 4) included 2 trials that used a 60 mg Fe/d control but were excluded due to using a 250 μg/d folic acid dose (2, 8, 9) Adu-Afarwuah et al. [6] Roberfroid et al. [12] Christian et al. [13] Kaestel et al. [14] Osrin et al. [15] Fawzi et al. [8] Zeng et al. [16] Bhutta et al. [11] Persson et al. [5] Ashorn et al. [7] Sunwang et al. [9] Overall Pooled Effect (2) . Lending further support to this hypothesis, a meta-analysis of iron supplementation trials found that every 10-mg increase in iron dose linearly decreased the risk of low birth weight by 3% (95% CI: 2%, 5%) up to 66 mg (17) . Although this iron meta-analysis was not completed for neonatal survival, low birth weight is an important risk factor for neonatal mortality (18) . We argue that programs considering implementation of MMS in pregnancy should consider using a formulation with an iron dose similar to their current iron supplementation recommendations (i.e., MMS that contains 60 mg Fe in settings where 60 mg Fe is currently used).
The concern and related evidence that MMS may potentially increase the risk of neonatal mortality have evolved over time. Initially, reports from a trial conducted in Nepal raised concern that increased birth size due to MMS may increase the risk of cephalopelvic disproportion and neonatal asphyxia, particularly among women of short stature (13, 19) . This was followed by a 2011 review by Haider et al. (20) that noted increased risk of neonatal mortality among the subgroup of trials where <60% of women delivered in a health facility (RR: 1.47; 95% CI: 1.13, 1.92). However, the recent IPD metaanalysis, which used the gold standard, individual-level, analytic approach, revealed no indication that MMS increased the risk of stillbirth or neonatal mortality among women with short statures (height <150 cm) or among women delivering without a skilled birth attendant (2) . In fact, after pooling all available data, MMS was found to significantly decrease the risk of infant mortality for infants born to women without access to a skilled birth attendant (∼18% risk reduction) (2) . The IPD analysis provides stronger causal evidence at individual level, therefore we conclude there is no evidence of harm associated with MMS and clear evidence of benefit.
Our update of the WHO subgroup analysis showed no increased risk of neonatal mortality and the results are consistent with the findings of the updated 2017 Cochrane Review and our recent IPD meta-analysis which found that MMS did not increase the risk of neonatal mortality overall or in any of 26 subgroups of pregnant women and newborns (2, 4) . In fact, we found previously that MMS clearly reduces the risk of neonatal and infant mortality for female infants (2) . Given the new and consistent evidence, WHO should promptly review their statements regarding the potential neonatal mortality risks associated with MMS and re-evaluate the overall benefits of implementing MMS as a public health program.
